SHARON, Pa., Jan. 31 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (OTC Pink Sheets: NNLX) will hold an informational meeting in Sarasota, Florida on February 12, 2007. Although the company has distributed proxies to NNLX shareholders, the company intends to utilize the February meeting solely to increase shareholder understanding of the company. The company is considering a spin-off of its medical technology into a separate company. However, this and other matters will be further clarified and voted upon at a second meeting, which will be announced at a later date. Mitchell S. Felder, M.D., CEO of NanoLogix, Inc. stated, "With a new year upon us, now is an excellent time to update our valued shareholders on the progress of the company to date, as well as on future growth opportunities. In 2006, the company reached significant milestones in the development and proprietary design of the hydrogen bioreactors. As an extension of our production of hydrogen from wastewater, we will begin offering conversion of gasoline- or diesel- powered engines to operate cleanly and efficiently on hydrogen gas (H2), through our relationship with Precision Performance Co. of Ohio. We also are working on a number of patent applications for the conversion of gasoline/diesel engines to hydrogen. This year, NanoLogix plans to pick up the pace of project management, research and development, and sales and marketing as management pursues its growth strategy to create a thriving business. With the demand for energy solutions growing, NanoLogix' focus should help to create substantial value for shareholders in 2007." About NanoLogix, Inc. NanoLogix is an industry innovator in the research, development and commercialization of nano-biotechnologies, applications and processes. The Company owns or has the rights to 32-patented technologies and also has 22 pending patent applications. The Company is currently focused on the production of hydrogen from agricultural feedstock, industrial wastewater and municipal waste streams to create new sources of energy. NanoLogix is presently operating a hydrogen bioreactor at Welch's Food and has recently signed an agreement with the City of Erie Wastewater Treatment Plant for a prototype bioreactor at Welch's Food and has recently signed an agreement with the City of Erie Wastewater Treatment Plant for a prototype bioreactor installation. Additionally, NanoLogix develops and markets diagnostic test kits for use in early detection of infectious diseases, and own a patent for the non-toxic induction of apoptosis ('cell suicide') for the treatment of cancer. For more information on the Company, visit: http://www.nanologix.net/. This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc. and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not the guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results. Contacts: NanoLogix, Inc. Investor Relations 724-346-1302 Andrew Barwicki 516-662-9461 or Peter Clark OTC Financial Network 781-444-6100 X 629 http://www.otcfn.com/nnlx DATASOURCE: NanoLogix, Inc. CONTACT: NanoLogix, Inc., +1-724-346-1302; or investors, Andrew Barwicki, +1-516-662-9461, or ; or Peter Clark of OTC Financial Network, +1-781-444-6100 X 629, or , for NanoLogix, Inc. Web site: http://www.nanologix.net/ http://www.otcfn.com/nnlx

Copyright